04:15 AM EDT, 08/13/2024 (MT Newswires) -- Dyne Therapeutics ( DYN ) reported late Monday Q2 net loss of $0.70 per diluted share, narrower than the $1.08 loss per share a year earlier.

Analysts polled by Capital IQ expected $0.67 loss per share.

The company reported no revenue for the quarter.

As of June 30, the company had a cash, cash equivalents, and marketable securities balance of $778.8 million, with an expected cash runway of until H2 2026.

Price: 43.00, Change: -0.07, Percent Change: -0.16